Olet siirtymässä toiselle sivustolle

Olet poistumassa Oy H. Lundbeck Ab:n ylläpitämältä sivustolta!

 

Olet siirtymässä sivustolle:

Peruuta

Tuotekehitysputki

Kehitysputkessa olevat hoidot

Tutkimus- ja kehitysryhmiemme tavoitteena on löytää aivosairauksien taustalla olevat mekanismit. Kuljemme yhdessä kohti tavoitetta kehittää ja tarjota uusia hoitomuotoja, jotka edistävät potilaiden hoidon standardeja sekä osoittavat ne aivosairauksien alueet, joissa on suurimmat kehitystarpeet.
Projekti Alue Faasi I Faasi II Faasi III Rekisteröinti
Eptinezumab (anti-CGRP mAb) Migreeni Filing

Vaikutusmekanismi

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab (anti-CGRP mAb) Episodic cluster headache 3

Vaikutusmekanismi

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole* Agitation in Alzheimer's disease 3

Vaikutusmekanismi

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* PTSD 3

Vaikutusmekanismi

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD (post-traumatic stress disorder) symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole 2-month injectable* Schizophrenia + Bipolar I disorder 1

Vaikutusmekanismi

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 (MAGL inhibitor)* Focal epilepsy, PTSD, MS spasticity 1

Vaikutusmekanismi

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and decrease neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including post-traumatic stress disorder (PTSD), focal epilepsy, and spasticity in patients with multiple sclerosis (MS).

* PTSD, focal epilepsy, and MS spasticity Ph1b studies have been initiated.

Lu AF82422 (anti-alpha-synuclein mAb) Multiple system atrophy 2

Vaikutusmekanismi

Lu AF82422 is a monoclonal antibody (mAb) targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 (D1-D2 agonist) Parkinson's disease 1

Vaikutusmekanismi

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG09222 (anti-PACAP mAb) Migreeni 2

Vaikutusmekanismi

Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.

Lu AF87908 (anti-Tau mAb) Tauopathies 1

Vaikutusmekanismi

Lu AF87908 is a monoclonal antibody (mAb) targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

More from Lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.

Investors

Detailed information related to Lundbeck’s financial performance. 

Understanding Brain Diseases

The journey to brain health starts with understanding the diseases in the brain.